Life Healthcare Group Holdings Limited
Life Healthcare Group Holdings Limited (LTGHF) Financial Performance & Income Statement Overview
Access detailed quarterly and annual financial reports for Life Healthcare Group Holdings Limited (LTGHF), covering cash flow, earnings, and balance sheets.
Life Healthcare Group Holdings Limited (LTGHF) Income Statement & Financial Overview
Analyze Life Healthcare Group Holdings Limited’s LTGHF earnings with segmented quarterly and yearly financial statement figures.
| Metric | Q4 2024 | Q2 2024 | Q4 2023 | Q2 2023 |
|---|---|---|---|---|
| Revenue | $13.93B | $5.93B | $7.35B | $15.29B |
| Cost of Revenue | $9.50B | $4.27B | $6.50B | $13.90B |
| Gross Profit | $4.43B | $1.66B | $849.00M | $1.39B |
| Gross Profit Ratio | $0.32 | $0.28 | $0.12 | $0.09 |
| R&D Expenses | $0.00 | $0.00 | $0.00 | $0.00 |
| SG&A Expenses | $1.51B | $1.10B | $0.00 | $492.00M |
| Operating Expenses | $2.62B | $1.11B | $0.00 | $1.02B |
| Total Costs & Expenses | $12.12B | $5.38B | $6.50B | $13.90B |
| Interest Income | $0.00 | $158.00M | $99.00M | $60.00M |
| Interest Expense | $0.00 | $220.00M | $161.00M | $417.00M |
| Depreciation & Amortization | $367.00M | $612.00M | $43812.00 | $1.20B |
| EBITDA | $2.26B | $1.87B | $1.15B | $2.54B |
| EBITDA Ratio | $0.16 | $0.32 | -$0.03 | $0.17 |
| Operating Income | $1.81B | $550.50M | $849.00M | $1.39B |
| Operating Income Ratio | $0.13 | $0.09 | $0.12 | $0.09 |
| Other Income/Expenses (Net) | -$129.00M | $491.50M | $135.00M | -$473.00M |
| Income Before Tax | $1.68B | $1.04B | $984.00M | $918.00M |
| Income Before Tax Ratio | $0.12 | $0.18 | $0.13 | $0.06 |
| Income Tax Expense | $227.00M | $311.00M | $178.00M | $305.00M |
| Net Income | $1.33B | $3.50B | -$283.00M | $547.00M |
| Net Income Ratio | $0.10 | $0.59 | -$0.04 | $0.04 |
| EPS | $0.89 | $2.43 | -$0.20 | $0.38 |
| Diluted EPS | $0.90 | $2.41 | -$0.20 | $0.38 |
| Weighted Avg Shares Outstanding | $1.47B | $1.44B | $1.44B | $1.44B |
| Weighted Avg Shares Outstanding (Diluted) | $1.46B | $1.45B | $1.44B | $1.45B |
The company's financials show resilient growth, with revenue advancing from $15.29B in Q2 2023 to $13.93B in Q4 2024. Gross profit remained healthy with margins at 32% in Q4 2024 compared to 9% in Q2 2023. Operating income hit $1.81B last quarter, sustaining a consistent 13% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at $2.26B. Net income dropped to $1.33B, while earnings per share reached $0.89. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan